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This weekly COVID-19 health evidence summary (HES) is based on 3.5 hours of desk-based 
research. The summary is not intended to be a comprehensive summary of available evidence on 
COVID-19 but aims to make original documents easily accessible to decision makers which, if 
relevant to them, they should go to before making decisions. 






























• The authors analysed 
public health data from 
Parana, Brazil between 
01.09.2020 and 
17.03.2021. During that 
time period, 8853 
deaths from COVID-19 
were recorded (from 
553,518 cases 
registered) .  
• Between September 
2020 and January 
2021, case fatality rates 
amongst all ages was 
either declining or 
stabilised, however, in 
February 2021 an 
increase was 
observed.   
• A P.1 variant of SARS-
CoV-2 was officially 
identified in this region 
on 16th February 2021, 
and on 3rd March 2021, 
accounted for 70.3% of 
tested samples. 









increases in case 
fatality rates for young 
and middle aged adults 
(above 20 years of age) 
in February 2021 
compared to January 
2021. 
• The authors call for 
further investigations to 
explore these findings, 
and increased public 
health interventions. 
24.03.2021 The first and 
second 









• A cross-sectional study 
explored 
epidemiological data 
across all 55 African 
Union member states. 
This research analysed 
incidence rates, case 
fatality ratios,  tests per 
case ratio and growth 
rates. It also considered 
the public health and 
social measures in 
place. 
• Two waves of the 
pandemic during Feb 
14th 2020 to 31st 
December 2020 were 
analysed. 
• Regionally, the 
southern region 
accounted for the 
highest number of 
cases (640/100000) 
and deaths (46.4%) 
with South Africa 
accounting for 38% of 
cases 
• Six countries (SA, 
Morocco, Ethiopia, 
Kenya, Egypt and 
Nigeria) accounted for 
62% of all test 
performed. All 55 AU 
member states had 
COVID-19 testing 
capacity by July 2020. 
• Six countries (Central 
African Republic, Cabo 
Verde, Côte d’Ivoire, 







Ghana) were all 
reporting COVID-19 
recovery rates equal to or 
greater than 98% 
• Peak weekly incidence 
was reported in mid 
July for the first wave. 
The authors report that 
at time of conducting 
analysis, the second 
wave had not yet 
reached its peak, 
however, it was already 
higher than the first 
(30% increase in 
weekly reporting) and 
was described as ‘fast 
evolving’. 
• The authors report that 
more stringent public 
health and social 
measures (PHSMs) 
were implemented in 
the first wave, and 
discuss about the 
potential for PHSM 
adherence fatigue, and 
the need for sustained 















• The burden of COVID-
19 in Yemen is 
reportedly 
unclear.  Official 
reported figures are 
thought to be 
underestimated due to 
low testing capacity, 
during a prolonged 
crisis and significant 
disruption to the health 
service. 
• In this article, the 
authors use a novel 
approach of geospatial 
analysis to estimate 
excess deaths in Aden, 
Yemen, using satellite 
imagery and Civil 
Registry office records. 
78 observations were 









1500 excess deaths are 
estimated to have 
occurred during 1 April 
to 6 July 2020 and 
2120 up to 19 
September. 


















• A systematic review 





19 throughout the 
course of infection. 
• 28 articles published 
between 01.01.2020 
and 09.12.2020 were 
included, which found 
one-fourth (25% 
(95%CI: 16–38)) of 
COVID-19 cases were 
asymptomatic 


























• Point of care antigen 
and antibody 
diagnostic tests have 
the benefits of being 
done outside of 
centralised 
laboratories, and can 
produce results very 
quickly, however the 

















there is a need for 
more evidence on 
performance of these 
tests in LMICs. The 
authors conducted a 
clinical prospective 
study to evaluate 
antigen tests in 
comparison to PCR 
and antibody in 
comparison to ELISA. 
• Five rapid tests 
(Innovita, Wondfo, SD 
Biosensor, and 
Runkun tests, and 
nasopharyngeal 
swabs for SARS-CoV-
2 antigen using the SD 
Biosensor tests) were 
evaluated in both 
symptomatic (n=570) 
and non-symptomatic 
(n=625) adults (above 
21 years old). 347 
(29%) tested SARS-
CoV-2 PCR-positive, 
223 (19%) rapid 
diagnostic test 
antigen-positive, and 
478 (40%) rapid 
diagnostic test 
antibody-positive.  
• Antigen-based rapid 
diagnostic test 
sensitivity was 80·0% 
(95% CI 71·0–88·0) in 
the first 7 days after 
symptom onset, but 
antibody-based rapid 
diagnostic tests had 
only 26·8% sensitivity 
(18·3–36·8). Antibody 
rapid diagnostic test 
sensitivity increased to 
76·4% (70·1–82·0) 14 
days after symptom 
onset.  
• An antigen-based 
retrospective algorithm 
designed by public 
health experts was 
applied to 
symptomatic patients 
and  showed 94·0% 
sensitivity and 91·0% 
specificity in the first 7 




algorithm showed a 
sensitivity of 34% 
(95% CI 23·0–44·0) 
and a specificity of 
92·0% (88·0–96·0). 
• The authors 
conclude  that rapid 
diagnostic tests could 
be incorporated into 
efficient testing 
algorithms as an 
alternative to PCR to 
decrease diagnostic 






















• The objective of this study 
was to assess the effect of 
IL‐6 blocking agents 
compared to standard care 
alone or with placebo on 
efficacy and safety 
outcomes in COVID‐19. A 
search was done of  World 
Health Organization 
(WHO) International 
Clinical Trials Registry 
Platform (up to 11 
February 2021) and the L‐
OVE platform, and 
Cochrane COVID‐19 
Study Register to identify 
trials up to 26 February 








Control Trial (including 3 
pre-prints) were included 
which 
analysed  tocilizumab (9) 
and sarilumab (1). In total 
6896 people with COVID‐
19 were included in these 
RCTs. 
• The authors conclude 
that  tocilizumab reduces 
all‐cause mortality at day 
28 (D28) and may slightly 
reduce serious adverse 
events compared to 
standard care alone or 
placebo (on average, 32 
fewer people per 1000 
died when treated with 
tocilizumab plus standard 
care), however there is 
uncertainty around the 
effect on mortality at ≥ 
D60). 
• For sarilumab, the 
evidence is uncertain 
about the effect on all‐
cause mortality at D28. 
• A further 39 RCTs of IL‐6 
blocking agents with no 
results are currently 
registered. The authors will 
continue to update the 
review as published data 
becomes available. 



















• To better understand 
the impacts of COVID-
19 on TB in high TB 
burden settings, the 
authors analysed an 
electronic TB register in 
Blantyre, Malawi, with 
the primary objective to 
understand impact on 











objectives were to 
understand how this is 
affected by sex, health 
facility or HIV status. A 
qualitative study of 12 
interviews with TB 
officers was then 
conducted to 
understand underlying 
cases for change in 
notification of TB. 
• In April 2020 there was 
an abrupt decline in TB 
notification by 35.9% 
(95% CI 22.1 to 
47.3%). However, the 
authors report this was 
subsequently followed 
by an increase in TB 
notifications at a rate of 
4.40% per month (0.59 
to 8.36%). 
• The authors report that 
there were 333 fewer 
TB notifications during 
April to December 
2020, compared to 
models created which 
estimates notifications if 
no pandemic had 
occurred. This is 
equivalent to a 23.7% 
reduction in TB 
notifications (95% CI 
21.4 to 26.0%). Women 
and girls had a larger 
proportional decline 
compared to men and 
boy. 
• Interviews suggest this 
under-notification of TB 
could be due to fear of 
contracting COVID-19, 
Health Facility closure, 
impacts on healthcare 
access, similarity of 
symptoms between the 
two conditions, and 
reduced health worker 






















• Domestic workers in Latin 
American countries are 
thought to be at increased 
risk of COVID-19 due to 
pre-existing health 




• An online survey was 
done across 14 Latin 
American countries with 
2650 respondents. 96% of 
all participants were 
women. The survey found 
that nearly 25% of 
respondents had at least 
one pre-existing condition 
which is considered a risk 
factor for COVID-19. An 
average only 56% 
reported being given 
adequate Personal 
Protective Equipment by 
their employers, and 5 % 
reported experiencing 
violence or mistreatment 
during the crisis. 
• In conclusion, the authors 
report that domestic 
workers during COVID-19 
pandemic face many risks 
(both new and 
exacerbations of pre-
existing risks) which 
increase their vulnerability 



















• During complex 
emergencies such as 
epidemics,  gender-based 
violence (GBV) can 
increase. This has also 
been found during the 
COVID-19 pandemic. A 
study in Kenya explored 
how government policies 












impacted women and 
girls, with a specific focus 
on those hard to reach. 
Interviews were 
conducted with 37 
stakeholders from GBV 
and sexual reproductive 
health (SRH) 
organisations/services. 
• Results suggest that 
adolescent girls and sex 
workers are the most 
vulnerable to GBV. 
Female Genital Mutilation 
is also reportedly 
increasing. Access to 
supportive services has 
decreased due to schools 
and community groups 
closing, and a lack of 
prioritisation of essential 
SRH services at the 






Comments, Editorials, Opinions, Blogs, News 
Publication 
date 
Title/URL Journal | Article type 
26.03.2021 Why we need to share vaccine doses now and why 
COVAX is the right way to do it 
Wellcome| News 
26.03.2021 Operation Warp Speed: implications for global vaccine 
security 
The Lancet Global 
Health | Viewpoint 
26.03.2021 How COVID-19 Affects the Brain JAMA psychiatry 
24.03.2021 Research to ensure continuity of TB care amid COVID-
19 
TDR| News release 
24.03.2021 Human rights and fair access to COVID-19 vaccines: 
the International AIDS Society–Lancet Commission on 
Health and Human Rights 
The Lancet| Comment 
23.03.2021 The Coronavirus Pandemic 1 Year On—What Went 
Wrong? 
JAMA Network| JAMA 
Forum 
21.03.2021 Hypercoagulability in COVID-19: A review of the 
potential mechanisms underlying clotting disorders 
SAGE Open Medicine| 
Review 
   
 
Dashboards & Trackers   












  Diagnostics   Treatments   Vaccines 
WHO sitreps  WHO Africa  Ghana  COVID-NMA  WHO    FIND SARS-
CoV-2 Test 
Tracker 
  Global COVID-
19 Clinical Trial 
Tracker 
  CEPI 
WHO dashboard  African 
Arguments  


















Nigeria CDC  Norwegian 
Institute of Public 
Health  
Cytel   Serology-based 
tests for COVID-
19 
  Solidarity trial  COVID-19 
Oxford Vaccine 
Trial 





US NIH   Our World in 
Data: C19 
Testing 





Our World in 
Data  
  Singapore   Our World in 
Data: C19 Policy 
responses 
COVID-evidence      Our World in 
Data: COVID-
19 vaccinations  
Global 5050    UK   IFPRI COVID-19 
Policy Response 
Portal 




  US   COVID-19 
Primer 
Clinicaltrials.gov        
Humanitarian 
Data Exchange  
     NIH LitCovid  UKCDR       
Information is 
Beautiful  
     WHO COVID-19 
Database 
        
LSHTM                
HealthMap 
(cases) 
              
The Commons 
Project 
              
SeroTracker                
   
 
C19 Resource Hubs 


















LSTM Stop TB 
Partnership 








  IDA 






















































Direct C19 blog 
series 






















Institute of Public 
Health 
    






Oxford Centre for 
Evidence-based 
Medicine 
    
UNICEF   The Lancet  HEART     
UNESCO   medRxiv 
and bioRxiv 
(Preprints) 
 UKRI     
UN WFP   NEJM  Evidence Aid     
GOARN   Oxford 
University 
Press 
 NIH     
EPI-WIN   PLoS IFPRI Resources 
and Analyses of 
C19 Impact 
    




    
Our World in 
Data 
  Science  Health systems 
Global 





  Springer 
Nature 
      
Reliefweb   SSRN 
(Preprints)  













      
WorldPop           
Flowminder           





    
  
GISAID           
 
  
Online learning & events 
 Date Title/URL Online 
learning/event 
Duration Lead 
07.04.2021 Public webinar 'The 
RECOVERY Trial: one 
year on' 
Webinar 1h Nuffield Department 
of Population Health 
25 March 
2021 
UK Public Health Rapid 
Support Team: Latest 
research & scientific 
insights 
Webinar 1h LSHTM 
18 March 
2021 
Africa taking charge of 
its future: prioritizing 
gender equality in the 
path to recovery 
Webinar 1h 30 CGD 
10 March 
2021 
Equity and scale in 
global immunization: 
new evidence from 
Nigeria on cash 
transfers for vaccination 
Webinar 1h 15 CGD 
9 March 
2021 
COVID-19 vaccines and 
Africa: where do we 









Diseases in the COVID 
era 




training for health 
workers 
Online training 3h  WHO 
14.01.2021 Evidence to impact in 
crisis: how have we 
measured up during the 
COVID-19 pandemic? 
Webinar 1h 30 CGD 
04.12.2020 COVID-19, supply chain 
resilience and global 
trade 
Webinar 1h CGD 
03.12.2020 More money for health 
services: What is the 
tole of PFM in the “new 
normal”? 




1h 30 Joe Kutzin 
01.12.2020 Solutions and support 
for the mental wellbeing 
of community health 
workers on the COVID-
19 frontline 
Webinar   HSG TWG on CHWs 
with The George 
Institute for Global 
Health 
19.11.2020 Looking at the pandemic 
with a gender lens 
Live Twitter 
conversation 
  SSHAP 
16.11.2020 HIFA and WHO 
collaborate to promote 
sharing of experience 
and expertise around 
the maintenance of 
essential health services 




starting 16 Nov 
  HIFA 
10.11.2020 COVID-19 vaccine 
predictions part 2: 
estimating the time 
before we approve 
efficacious COVID-19 
vaccines 
Online event 1h30 CGD 
16.10.2020 Financing a Global 
Public Health Response 
Online event 1h30 CGD 
02.10.2020 Understanding and 
Improving COVID-19 
Vaccine Portfolio 
Online event 1h30 CGD 
21.09.2020 Mitigating the Economic 
and Health Impact of 
COVID-19 across Africa 
Online event 1h30 CGD, GF, AU 
June 2020 OpenWHO, the free, 
open-access learning 
platform for health 
emergencies, now offers 
10 online courses 
related to COVID19. 










Nursing in Times of 
Crisis 






School of Nursing 
Available 
now 
WHO Academy and 
WHO Info mobile 
applications 




Modelling and Policy 
Online learning 2 weeks 








11.5.2020 COVID-19 Contact 
Tracing course 
Online learning 5 hours Johns Hopkins 




Virtual Evidence Weeks 5 sessions 1h 30 International Initiative 







COVID-19 Open online 
brief with Dr David 
Nabarro 









COVID-19: methods for 
detection, prevention, 
response and control 




19: Real-time training 
for the coronavirus 
disease outbreak 







COVID-19: Tackling the 
Novel Coronavirus 
Online learning 3 weeks 
















Online learning 3 weeks 







COVID-19 Critical Care: 
Understanding and 
Application 
Online learning 5 weeks 





Edinburgh & Royal 
College of Physicians 
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Rapid review methodology 
The rapid weekly search for peer-reviewed literature is carried out through a PubMed search with the following 
keywords (“COVID-19” OR “severe acute respiratory syndrome coronavirus 2” OR “2019-nCoV” OR “SARS-CoV-
2” OR “2019nCoV” OR “coronavirus” ) AND (“Africa” OR “South Asia” OR “Developing” OR “low-income” OR “low 
income” OR “lower-middle income” OR “low and middle income” OR “LMIC” OR “LIC” OR “global south”) OR 
(“poverty”) OR (“equity” OR “equities”), restricted to articles published in the previous 2 to 3 days, in English. This 
is complemented by a search of the homepage of the following high-impact global health journals: The Lancet 
journals, New England Journal of Medicine, Nature, JAMA, Annals of Internal Medicine, Cochrane Reviews, BMJ 
Global Health, the PLoS journals and a Twitter search of their Twitter pages. A search also of preprints from 
bioRxiv and medRxiv. Please note that papers that have not been peer-reviewed are highlighted in red. All 
primary research papers that relate to the primary and secondary impacts of the COVID-19 response in LMICs, 
and disease control and health system responses are included. Articles related to tackling the secondary impacts 
on other sectors are not included. Additional commentaries, opinions, and commissioned pieces are selected 
based on relevance. 
  
The search for dashboards, guidelines, tools, editorials, comments, blogs, opinions and news is through the 
academic journals listed above, C19 resource hubs and following lead academics and professionals on Twitter. 
About this report  
This weekly COVID-19 health evidence summary (HES) is based on 3.5 hours of desk-based research. The 
summary is not intended to be a comprehensive summary of available evidence on COVID-19 but aims to make 
original documents easily accessible to decision makers which, if relevant to them, they should go to before 
making decisions. The HES are not intended to replace medical or professional advice and the researcher or the 
K4D consortium cannot be held responsible for any decisions made about COVID-19 on the basis of the HES 
alone. K4D services are provided by a consortium of leading organisations working in international development, 
led by the Institute of Development Studies (IDS), with Education Development Trust, Itad, University of Leeds 
Nuffield Centre for International Health and Development, Liverpool School of Tropical Medicine (LSTM), 
University of Birmingham International Development Department (IDD) and the University of Manchester 
Humanitarian and Conflict Response Institute (HCRI). 
This evidence summary was prepared for the UK Government’s Foreign, Commonwealth 
and Development Office (FCDO) and its partners in support of pro-poor programmes. Except 
where otherwise stated, it is licensed for non-commercial purposes under the terms of the 
Open Government Licence v3.0. K4D cannot be held responsible for errors, omissions or 
any consequences arising from the use of information contained in this health evidence 
summary. Any views and opinions expressed do not necessarily reflect those of FCDO, K4D 
or any other contributing organisation.  
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